International Edition
Latest News
News

Phoenix VA Announces Research Agreement for Alzheimer’s Plasma Exchange Study

The Phoenix VA Health Care System, the Arizona Veterans Research and Education Foundation, AmBARI Healthcare and the Young Blood Institute announced a cooperative research agreement Thursday to test an optimized plasma-exchange protocol in veterans with mild cognitive impairment…

Phoenix VA Announces Research Agreement for Alzheimer's Plasma Exchange Study

The Phoenix VA Health Care System, the Arizona Veterans Research and Education Foundation, AmBARI Healthcare and the Young Blood Institute announced a cooperative research agreement Thursday to test an optimized plasma-exchange protocol in veterans with mild cognitive impairment (MCI) and prodromal Alzheimer’s disease.

The AmBARI study, registered as VA Protocol #1859907, will enroll up to 56 veterans in a randomized, controlled trial led by principal investigator S. Mitchell Harman, MD, PhD, at the Phoenix VA. Researchers will use PET-CT imaging with the NAV-4694 tracer to measure changes in brain amyloid burden as the primary endpoint, according to the announcement.

AmBARI Healthcare is funding the study through its partnership with the Young Blood Institute, which is providing protocol design and access to apheresis systems, biomarkers and imaging technologies from several strategic partners. The Arizona Veterans Research and Education Foundation facilitates the public-private partnership.

Ambari healthcare tranzlogo
Photo: prnewswire.com

The protocol draws on the Grifols AMBAR trial and real-world experience at Ace Alzheimer Center Barcelona. Both demonstrated a 61 percent success rate in delaying or arresting disease progression in early to moderate Alzheimer’s patients, with 11 to 15 percent showing memory improvement, the organizations said. The AMBAR trial studied 498 patients, while Ace Barcelona has delivered more than 2,100 full-volume therapeutic plasma exchange procedures as standard care.

Young Blood Institute pre-clinical studies also showed plasma exchange can clear amyloid beta in cognitively unimpaired subjects. YBI and Ace Barcelona collaborated on protocol optimization for the VA study.

Professor Colin Masters, MD, global coordinating principal investigator for the Young Blood Institute, said the optimized protocol aims to validate the amyloid hypothesis by demonstrating how human serum albumin binds Aβ42 and Aβ40 with high affinity to actively clear amyloid beta.

“This CRADA represents an important step in our ongoing efforts to bring innovative, translational research directly to our veterans affected by this devastating disease,” said Elijah J. Ditter, medical center director of the Phoenix VA Health Care System. “We are committed to exploring promising new approaches that have the potential to meaningfully improve care within the VA system.”

Dr. Samuel M. Aguayo of the Phoenix VA added that the agreement allows rigorous evaluation of therapeutic plasma exchange in a controlled veteran population. Jeremy Greene, MS, executive director of the Arizona Veterans Research and Education Foundation, said the partnership enables novel treatments for veterans that often extend to the general population.

S. Mitchell Harman graduated from Miami Beach High School in 1960 and earned a BS in biology from Emory University in 1964. He completed a six-year M.D./Ph.D. program at the SUNY Health Science Center in Brooklyn in 1970 and a residency in internal medicine at Yale-New Haven in 1972.

Commissioned in the United States Public Health Service in 1972, he served as a Clinical Associate at the National Institutes of Health before joining the National Institute on Aging in Baltimore, where he founded a laboratory for the study of aging reproductive hormone systems and joined the Johns Hopkins University School of Medicine faculty.

Promoted to Captain (O6) in the USPHS, Harman served as Chief of the Endocrinology Section in the Laboratory of Clinical Physiology, acting Chief of that laboratory, and acting Clinical Director of the NIA. He became an Associate Professor of Medicine at Johns Hopkins in 1984.

Mark Urdahl, CEO of both AmBARI Healthcare and the Young Blood Institute, said the VA’s ability to rapidly translate research into real-world care drove the collaboration. The study operates under Phoenix VA Institutional Review Board oversight and federal regulations.

About the author: Newsroom

Newsroom at Archynewsy.